|
68 Companies |
|
87 Products |
|
87 Products |
|
71 Mechanisms of Action |
|
3 Trials |
|
597 News |
|
| «12345678910111213» |
- Trial withdrawal: Phoenix: Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis (clinicaltrials.gov) - Aug 8, 2013
P=N/A, N=0, Withdrawn, Sponsor: Bayer
Not yet recruiting --> Withdrawn
- Enrollment change: Phoenix: Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis (clinicaltrials.gov) - Aug 8, 2013
P=N/A, N=0, Withdrawn, Sponsor: Bayer
Not yet recruiting --> Withdrawn N=55 --> 0
- ||||| New P4 trial: A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis (clinicaltrials.gov) - Aug 1, 2013
P4, N=120, Recruiting, Sponsor: GlaxoSmithKline
- New P1 trial: Autologous Transplantation of Cultured Fibroblast on Amniotic Membrane in Patients With Epidermolysis Bullosa (clinicaltrials.gov) - Jul 23, 2013
P1, N=6, Completed, Sponsor: Royan Institute
- Trial completion: Autologous Transplantation of Cultured Fibroblast on Amniotic Membrane in Patients With Epidermolysis Bullosa (clinicaltrials.gov) - Jul 23, 2013
P1, N=6, Completed, Sponsor: Royan Institute
N=55 --> 0 Not yet recruiting --> Completed
- | New P2 trial: Efficacy Study of Dialyzed Leukocytes Extracts to Treat Paediatric Moderate Atopic Dermatitis (clinicaltrials.gov) - Jul 16, 2013
P2, N=58, Completed, Sponsor: National Polytechnic Institute, Mexico
- | lenalidomide / Generic mfg.
Enrollment closed: LENAKAP: Lenalidomide in Kaposi Disease Associated With HIV Infection (clinicaltrials.gov) - Jul 16, 2013
P2, N=35, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Efficacy Study of Dialyzed Leukocytes Extracts to Treat Paediatric Moderate Atopic Dermatitis (clinicaltrials.gov) - Jul 15, 2013
P2, N=58, Completed, Sponsor: National Polytechnic Institute, Mexico
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- | ligelizumab (QGE 031) / Novartis
Enrollment change: A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients (clinicaltrials.gov) - Jul 14, 2013
P2, N=22, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Completed N=30 --> 22
- Trial termination: Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States (clinicaltrials.gov) - Jul 11, 2013
P=N/A, N=119, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=30 --> 22 Recruiting --> Terminated
- Enrollment change: Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States (clinicaltrials.gov) - Jul 11, 2013
P=N/A, N=119, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Terminated N=600 --> 119
- ||| Trial completion: X-CORS: X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey (clinicaltrials.gov) - Jul 6, 2013
P=N/A, N=500, Completed, Sponsor: Edimer Pharmaceuticals
N=600 --> 119 Recruiting --> Completed
- recombinant ectodysplasin A1 (APO200) / Valerio Therap, Pierre Fabre
Enrollment open, IO biomarker: Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) (clinicaltrials.gov) - Jul 2, 2013
P2, N=6, Recruiting, Sponsor: Edimer Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Recruiting
- |||| Eucrisa (crisaborole) / Pfizer
Trial completion: Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis (clinicaltrials.gov) - Jun 20, 2013
P2, N=86, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- timbetasin topical (RGN-137) / RegeneRx
Trial initiation date: A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa (clinicaltrials.gov) - Jun 6, 2013
P2, N=30, Terminated, Sponsor: RegeneRx Biopharmaceuticals, Inc.
Active, not recruiting --> Completed Initiation date: Jan 2005 --> Feb 2006
- Fluzone (influenza vaccine) / Sanofi, Fluzone Intradermal Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion: Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study (clinicaltrials.gov) - May 22, 2013
P=N/A, N=316, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Jan 2005 --> Feb 2006 Active, not recruiting --> Completed
- ||||| Dupixent (dupilumab) / Sanofi, Regeneron
Biomarker, New P2 trial: Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - May 20, 2013
P2, N=380, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
- Trial withdrawal: Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 19, 2013
P=N/A, N=0, Withdrawn, Sponsor: Lotus Tissue Repair, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Biomarker, Trial termination: Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias (clinicaltrials.gov) - May 19, 2013
P=N/A, N=28, Terminated, Sponsor: Duke University
Not yet recruiting --> Withdrawn Recruiting --> Terminated
- Enrollment change: Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 19, 2013
P=N/A, N=0, Withdrawn, Sponsor: Lotus Tissue Repair, Inc.
Recruiting --> Terminated N=80 --> 0
- Biomarker, Enrollment change: Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias (clinicaltrials.gov) - May 19, 2013
P=N/A, N=28, Terminated, Sponsor: Duke University
N=80 --> 0 N=300 --> 28
- Zoryve (roflumilast cream) / Arcutis
New P2 trial: Topical Roflumilast in Adults With Atopic Dermatitis (clinicaltrials.gov) - May 15, 2013
P2, N=40, Recruiting, Sponsor: Takeda Pharma A/S
- Trial completion: The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) (clinicaltrials.gov) - May 12, 2013
P4, N=6, Completed, Sponsor: Maastricht University Medical Center
N=300 --> 28 Enrolling by invitation --> Completed
- | cyclosporine / Generic mfg.
Trial completion: METHODA: Study of Methotrexate Efficacy Versus Cyclosporine in Moderate to Severe Atopic Dermatitis Patients (clinicaltrials.gov) - May 12, 2013
P3, N=100, Completed, Sponsor: Hospices Civils de Lyon
Enrolling by invitation --> Completed Recruiting --> Completed
- | New P1 trial: Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream (clinicaltrials.gov) - May 8, 2013
P1, N=26, Recruiting, Sponsor: LEO Pharma
- LEO 29102 / LEO Pharma
Trial termination: Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. (clinicaltrials.gov) - Apr 29, 2013
P1, N=58, Terminated, Sponsor: LEO Pharma
Recruiting --> Completed Active, not recruiting --> Terminated
- LEO 29102 / LEO Pharma
Enrollment change: Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. (clinicaltrials.gov) - Apr 29, 2013
P1, N=58, Terminated, Sponsor: LEO Pharma
Active, not recruiting --> Terminated N=74 --> 58
- colestipol / Generic mfg.
Trial completion: Sorbent Therapy of the Cutaneous Porphyrias (clinicaltrials.gov) - Apr 28, 2013
P2/3, N=4, Completed, Sponsor: Brigham and Women's Hospital
N=74 --> 58 Active, not recruiting --> Completed
- |||||||||| bepotastine immediate release / Generic mfg.
New P3 trial: A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis (clinicaltrials.gov) - Apr 24, 2013
P3, N=303, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
- Orfadin (nitisinone) / Astellas, SOBI
New P1/2 trial: Nitisinone for Type 1B Oculocutaneous Albinism (clinicaltrials.gov) - Apr 22, 2013
P1/2, N=8, Recruiting, Sponsor: National Eye Institute (NEI)
- Trial completion: A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis (clinicaltrials.gov) - Apr 21, 2013
P4, N=20, Completed, Sponsor: Derm Research, PLLC
Active, not recruiting --> Completed Recruiting --> Completed
- REGN846 / Regeneron
Enrollment change: Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis (clinicaltrials.gov) - Apr 17, 2013
P1/2, N=19, Terminated, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Completed N=60 --> 19
- Trial completion: Risk of Asthma in Infants With Atopic Dermatitis (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=120, Completed, Sponsor: Indiana University School of Medicine
N=60 --> 19 Active, not recruiting --> Completed
- ||||| tacrolimus topical / Generic mfg.
New P4 trial: An Efficacy and Safety Study of Tacrolimus Ointment in Adult Participants With Atopic Dermatitis (clinicaltrials.gov) - Apr 9, 2013
P4, N=74, Completed, Sponsor: Janssen-Cilag Ltd.,Thailand
- ||||| New P2 trial: An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Apr 4, 2013
P2, N=151, Completed, Sponsor: PreCision Dermatology, Inc.
- Stelara (ustekinumab) / J&J
Clinical: Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis (clinicaltrials.gov) - Mar 10, 2013
P2, N=32, Recruiting, Sponsor: Rockefeller University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial initiation date: Phoenix: Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis (clinicaltrials.gov) - Mar 7, 2013
P=N/A, N=0, Withdrawn, Sponsor: Bayer
Not yet recruiting --> Recruiting Initiation date: Feb 2013 --> Oct 2013
- ||||| pegcantratinib (SNA-120) / Sienna
New P2 trial: A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis (clinicaltrials.gov) - Mar 7, 2013
P2, N=210, Recruiting, Sponsor: Creabilis SA
- | Stelara (ustekinumab) / J&J
New P2 trial: Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis (clinicaltrials.gov) - Mar 5, 2013
P2, N=32, Recruiting, Sponsor: Rockefeller University
- Enrollment closed: Trial of L-DOPA as a Treatment to Improve Vision in Albinism (clinicaltrials.gov) - Feb 27, 2013
P2, N=45, Active, not recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Initiation date: Feb 2013 --> Oct 2013 Recruiting --> Active, not recruiting
- Arcalyst (rilonacept) / Regeneron, Kiniksa
New P2 trial: Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA) (clinicaltrials.gov) - Feb 26, 2013
P2, N=15, Recruiting, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- ||| Enrollment change: Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP) (clinicaltrials.gov) - Feb 21, 2013
P2, N=263, Completed, Sponsor: Amphastar Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting N=200 --> 263
- |||| Trial completion: Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP) (clinicaltrials.gov) - Feb 21, 2013
P2, N=263, Completed, Sponsor: Amphastar Pharmaceuticals, Inc.
N=200 --> 263 Active, not recruiting --> Completed
- ||||||| Desonate (desonide gel) / LEO Pharma
Trial completion: Efficacy Emollient on Xerosis in Children With Atopic Dermatitis (clinicaltrials.gov) - Feb 19, 2013
P3, N=251, Completed, Sponsor: Pierre Fabre Medicament
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Zalain (sertaconazole) / Elder Pharma
New P2 trial: Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis (clinicaltrials.gov) - Feb 13, 2013
P2, N=80, Recruiting, Sponsor: Spirig Pharma Ltd.
- Trial termination: Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis (clinicaltrials.gov) - Feb 11, 2013
P=N/A, N=2, Terminated, Sponsor: Cosmetique Active International
Active, not recruiting --> Completed Recruiting --> Terminated; Sponsor Decision
- Enrollment change: Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis (clinicaltrials.gov) - Feb 11, 2013
P=N/A, N=2, Terminated, Sponsor: Cosmetique Active International
Recruiting --> Terminated; Sponsor Decision N=460 --> 2
- tacrolimus XR / Generic mfg.
New P2 trial: Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients (clinicaltrials.gov) - Feb 10, 2013
P2, N=10, Recruiting, Sponsor: UMC Utrecht
- | Dupixent (dupilumab) / Sanofi, Regeneron
Trial completion: Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD) (clinicaltrials.gov) - Feb 5, 2013
P2, N=31, Completed, Sponsor: Regeneron Pharmaceuticals
N=460 --> 2 Active, not recruiting --> Completed
- ||||| fevipiprant (QAW039) / Novartis
New P2 trial: Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis. (clinicaltrials.gov) - Feb 5, 2013
P2, N=92, Recruiting, Sponsor: Novartis Pharmaceuticals